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Abstract
Introduction 17β-estradiol (E2) can rapidly induce cAMP
production, but the conditions under which these cAMP levels
are best measured and the signaling pathways responsible for
the consequent proliferative effects on breast cancer cells are
not fully understood. To help resolve these issues, we compared
cAMP mechanistic responses in MCF-7 cell lines selected for
low (mERlow) and high (mERhigh) expression of the membrane
form of estrogen receptor (mER)-α, and thus addressed the
receptor subform involved in cAMP signaling.
Methods MCF-7 cells were immunopanned and subsequently
separated by fluorescence activated cell sorting into mERhigh
(mER-α-enriched) and mERlow (mER-α-depleted) populations.
Unique (compared with previously reported) incubation
conditions at 4°C were found to be optimal for demonstrating
E2-induced cAMP production. Time-dependent and dose-
dependent effects of E2 on cAMP production were determined
for both cell subpopulations. The effects of forskolin, 8-CPT
cAMP, protein kinase A inhibitor (H-89), and adenylyl cyclase
inhibitor (SQ 22,536) on E2-induced cell proliferation were
assessed using the crystal violet assay.
Results We demonstrated a rapid and transient cAMP increase
after 1 pmol/l E2 stimulation in mERhigh cells; at 4°C these
responses were much more reliable and robust than at 37°C
(the condition most often used). The loss of cAMP at 37°C was
not due to export. 3-Isobutyl-1-methylxanthine (IBMX; 1 mmol/l)
only partially preserved cAMP, suggesting that multiple
phosphodiesterases modulate its level. The accumulated cAMP
was consistently much higher in mERhigh cells than in mERlow
cells, implicating mER-α levels in the process. ICI172,780
blocked the E2-induced response and 17α-estradiol did not
elicit the response, also suggesting activity through an estrogen
receptor. E2  dose-dependent cAMP production, although
biphasic in both cell types, was responsive to 50-fold higher E2
concentrations in mERhigh cells. Proliferation of mERlow cells was
stimulated over the whole range of E2concentrations, whereas
the number of mERhigh  cells was greatly decreased at
concentrations above 1 nmol/l, suggesting that estrogen over-
stimulation can lead to cell death, as has previously been
reported, and that mER-α participates. E2-mediated activation of
adenylyl cyclase and downstream participation of protein kinase
A were shown to be involved in these responses.
Conclusion Rapid mER-α-mediated nongenomic signaling
cascades generate cAMP and downstream signaling events,
which contribute to the regulation of breast cancer cell number.
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Introduction
It has long been recognized that cAMP is an important
intracellular messenger that is capable of regulating diverse
functions such as steroidogenesis in the ovary, sugar
metabolism in the liver, and contractility of the cardiac mus-
cle [1-5]. In addition to these crucial and specific physio-
logical functions, the cAMP pathway plays an important
regulatory role in the development of other complex cellular
states such as differentiation, proliferation, and synaptic
plasticity. Elevated levels of intracellular cAMP can inhibit
the growth of some cell types but stimulate the growth of
others. Among the cell types whose growth is stimulated by
cAMP are thyroid [6], pituitary [7], and normal human
breast epithelial cells in culture [8]. Several studies have
AC = adenylyl cyclase; CV = crystal violet; DCSS = medium with 4 × dextran-coated charcoal-stripped serum; DM = defined medium; E2 = 17β-
estradiol; ER = estrogen receptor; ERK = extracellular signal-regulated kinase; IBMX = 3-isobutyl-1-methylxanthine; MAPK = mitogen-activated pro-
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demonstrated that cAMP inhibits the growth of established
breast cancer cell lines and breast cancer cells in primary
culture [8-10]. However, such studies have not completely
resolved issues such as the effective levels of cAMP in dif-
ferent cell types, the roles played by other participants in
the signaling web that may cooperate to bring about differ-
ent outcomes, and any subpopulations of response-initiat-
ing receptors.
The intracellular cAMP level is determined by the rates of its
synthesis and clearance. It is synthesized from ATP via a
transmembrane adenylyl cyclase (AC), which is activated
by stimulatory Gs proteins coupled to cell surface receptors
(G-protein-coupled receptors). Clearance is regulated
either by cyclic nucleotide phosphodiesterases (PDEs) or
by an efflux mechanism that secretes or transports cAMP
out of cells [11]. The multiplicity of PDEs was recently
established [12], but the regulation and utilization of differ-
ent isoforms are experimental issues that remain unclear.
The influence of 17β-estradiol (E2) on MCF-7 breast can-
cer cell proliferation was previously assigned exclusively to
genomic mechanisms. However, it has been known for
some time that E2 can rapidly (within a few minutes) induce
cAMP production, and that this time frame is not compati-
ble with the multiple macromolecular synthetic events nec-
essary for genomic responses [13]. We have an
incomplete understanding of the conditions under which
cAMP responses are best measured, and of the participa-
tion of multiple enzymes in generating and degrading
cAMP. There are also reports that some MCF-7 cell sub-
lines either do not respond or do not reliably generate this
response (personal communications from many laborato-
ries). Therefore, estrogen receptor (ER)-mediated mecha-
nisms that increase cAMP in MCF-7 and other responsive
cell types have not fully been explained. Here, we compare
cAMP responses in cell lines selected for low and high
expression of the membrane form of ER (mER)-α and thus
address the receptor subform that is involved in these
mechanisms. Additionally, we further probe the details of
mER-α-mediated activation of AC and the contributions of
PDEs to final signal levels, as well as subsequent cAMP-
dependent protein kinase A (PKA) activation and the regu-
lation of cell proliferation.
Methods
Cell immunoseparation and subculturing
MCF-7 cells originated from the Michigan Cancer Center.
We separated them into two subpopulations by immuno-
panning [14,15] using C-542 carboxyl-terminal ER-α anti-
body, provided by Drs Dean Edwards and Nancy Weigel.
This antibody is now commercially available from Stressgen
Biotechnologies (Victoria, Canada). Briefly, sterile antibody
on the surface of a petri plate bound cells at 4°C over a 1-
hour time period, and cells that attached to the plate
(mER+) were propagated separately from those that did not
bind (mERlow). Using the same antibody, mER+ cells were
then subjected to further separation via a fluorescence-acti-
vated cell sorter [16]. Cells selected by both types of
sequential separation are highly enriched for mER-α (mER-
high). Upon propagation, the separated cells were not exclu-
sively mER positive or negative, and consequently they
were named mERhigh and mERlow. We previously observed
this heterogeneity in similarly separated GH3/B6 cells
[15,17]. All subpopulations of MCF-7 cells were routinely
cultured in phenol-red free Dulbecco's modified eagle
medium (Gibco-BRL, Grand Island, NY, USA) supple-
mented with 10% heat-inactivated DSCS (defined/supple-
mented bovine calf serum; HyClone Laboratories, Inc.,
Logan, UT, USA) and 1% antibiotic–antimycotic (Gibco
Invitrogen Corporation, #15240-062). Cells used in the
experiments were between passage 8 and 14 after
separation.
Three days before each experiment, the cell growth
medium was replaced with medium containing 4 × dextran-
coated charcoal stripped serum (DCSS medium). Stripped
serum was produced by incubation with an equivalent vol-
ume of packed 0.25% weight/vol charcoal Norit A for 2
hours on a shaker at 4°C. The charcoal preparation had
previously been suspended in 0.0025% (weight/vol) dex-
tran T-70 (Sigma, St Louis, MO, USA) in 0.25 mol/l
sucrose, 1.5 mmol/l MgCl2, and 10 mmol/l HEPES (pH
7.6). The charcoal was pelleted at 500 g for 10 min and the
supernatant (stripped serum) decanted, and the process
was repeated four times. In other experiments we deprived
cells of serum 2–3 days before the experiment by placing
them in a defined medium (DM) consisting of phenol-red
free Dulbecco's modified eagle medium with 5 µg/ml insu-
lin, 5 µg/ml transferrin, 5 ng/ml selenium (using the stock
preparation from Sigma), and 0.1% bovine serum albumin.
cAMP response measurement
Cells were plated at a density of 0.25 × 106 per well in six-
well plates and then incubated in either DM or DCSS for 3
days before the experiment. In experiments in which hor-
mone treatments were performed at 37°C, on the day of the
experiment the cells were pretreated for 10 min with 1
mmol/l IBMX (3-isobutyl-1-methylxanthine; Sigma) and
then treated for different time intervals (3, 6, 10, 20, 30, 60
or 120 min) with 1 pmol/l E2 or ethanol vehicle (0.1%) in the
presence of IBMX. In experiments in which the hormone
treatment (as described above) was performed at 4°C,
cells were treated either in their growth plates or in suspen-
sion. For cell suspensions the cells were scraped from two
150 mm plates, pelleted at 1000 g, and resuspended in 3.5
ml DM. The incubation was then performed in 100 µl of cell
suspension with permanent agitation and the reaction was
terminated by spinning down the cells and washing them inAvailable online http://breast-cancer-research.com/content/7/1/R101
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cold DM. For attached cells, similar incubations were per-
formed in the growth dishes.
The specificity of this response for ER-α was tested with
ICI172,780 (Tocris Cookson Inc., Ellisville, MO, USA). The
cells were pretreated with ICI172,780 for 30 min (1 µmol/
l) and incubated for an additional 15 min after adding 1
pmol/l E2, or they were simultaneously treated for 15 min
with E2 and ICI172,780. As a negative control, we also
tested the time-dependent production of cAMP with 10
nmol/l 17α-estradiol (Sigma Aldrich, St Louis, MO, USA) –
an inactive E2 stereoisomer. Preparation of cell lysates and
quantification of intracellular cAMP were performed
according to the protocol provided with the cAMP detec-
tion kit (Amersham Pharmacia Biotech, Piscataway, NJ,
USA). Each value for cAMP was normalized against protein
concentration determined using a Bradford (Bio Rad, Her-
cules, CA, USA) protein detection kit.
Cell proliferation
Cells were plated at a density of 1000 or 2000 cells per
well in 96-well plates. The next day the growth medium was
replaced with DCSS containing the hormone (E2) or other
treatments (forskolin, 8-CPT cAMP, H-89 plus E2, SQ22
536 plus E2). Controls for E2 treatment were done on a
separate plate, because we had previously determined that
low amounts of volatilized estrogens can affect responses
mediated via nongenomic signaling pathways [18]; control
treatments were with the vehicle in which test compounds
were solubilized (ethanol or dimethyl sulfoxide). In some
experiments the growth medium was replenished every
second day, and after 5 days the cells were fixed with 2%
paraformaldehyde/0.1% glutaraldehyde in PBS. The
number of the cells in each well was determined using the
crystal violet (CV) assay [19], which we modified previously
[17]. Briefly, the cells were incubated in 0.1% CV for 30
min at room temperature, excess dye was removed by three
brief rinses with ddH2O, the plates were air dried, and the
dye was extracted with 10% acetic acid, which was then
read in a plate reader (Wallac 1420; Perkin Elmer, Boston,
MA, USA) at 590 nm.
The utility of the CV assay in measuring cell number was
verified both in MCF-7 cells and in combination with immu-
nodetection plate assays for GH3/B6 cells [17]. We com-
pared CV results with DNA content measurements and
with cell number counts by hemocytometer and both
assays correlated very well (data not shown). Additionally,
we compared the CV method with the MTT assay (ATCC,
Manassas, VA, USA), which is often used to determine cell
number and viability. Different numbers of mERhigh and
mERlow cells (1000–7000) were plated in 96-well plates,
and fixed and treated with CV as described. Both sets of
data were approximated with a single linear regression line
(Fig. 1a). The number of cells determined by CV versus
MTT assays were linearly correlated (Fig. 1b).
Statistical analysis
Statistical differences between two sets of data were
determined using two-way analysis of variance. The dose–
response curves were fitted with a four-parameter Gaus-
sian distribution (Sigma Plot 8.0; Systat Software Inc.,
Point Richmond, CA, USA). The differences between the
entire curves were tested by comparing the sum of squares
of the residuals from each individual curve with the sum of
squares of the residuals of the combined curves by
applying a Microsoft Excel F test. P < 0.05 was considered
statistically significant.
Figure 1
Verification of the utility of the crystal violet (CV) assay for measuring cell number Verification of the utility of the crystal violet (CV) assay for measuring cell number. (a) Different numbers of MCF-7 cells enriched for membrane 
estrogen receptor-α (mERhigh) and MCF-7 cells depleted for membrane estrogen receptor-α (mERlow; 1000–7000/well) were plated, fixed with 2% 
paraformaldehyde/0.1% glutaraldehyde, and then quantified via the CV assay at 590 nm absorbance. (b) Different numbers of mERhigh cells were 
assessed in parallel with CV and MTT assays to demonstrate a linear correlation between these assays. The values are means for 28 samples ± 
standard error.Breast Cancer Research    Vol 7 No 1    Zivadinovic et al.
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Results
Optimal conditions for E2-induced cAMP accumulation 
and measurement in MCF-7 cells enriched and depleted 
for membrane ER-α
MCF-7 cell line enriched for membrane ER-α
We observed that the level and kinetics of cAMP accumu-
lation varied depending on the type of incubation medium,
the incubation temperature, and pretreatment with the PDE
inhibitor IBMX. In mERhigh MCF-7 cells, 1 pmol/l E2 induced
rapid and transient production of cAMP (Fig. 2a,2b,2c). At
the reduced temperature of 4°C in a completely defined
medium (Fig. 2a), a substantial increase in accumulated
cAMP was seen as compared with the levels achieved at
37°C (Fig. 2b). The response peak at 4°C was prolonged,
as the accumulated cAMP decreased gradually, even in the
absence of the PDE inhibitor IBMX, which is usually
included to inhibit the decay of cAMP and enhance the
response. The same level of accumulated cAMP was
obtained at 5, 15 and 30 min at 4°C, regardless of whether
the treatment was performed with cells attached to a plate
(Fig. 2a, open circles) or in suspension (Fig 2a, closed cir-
cles). However, after 30 min the cAMP level declined
abruptly in attached cells. The DCSS medium did not
increase cAMP production at 4°C (data not shown).
Figure 2
Optimization of conditions for 17β-estradiol (E2)-induced cAMP accumulation and measurement Optimization of conditions for 17β-estradiol (E2)-induced cAMP accumulation and measurement. (a–c) MCF-7 cells enriched for membrane estro-
gen receptor-α (mERhigh) and (d, e) MCF-7 cells depleted for membrane estrogen receptor-α (mERlow). All of the cells were stimulated with 1 pmol/
l E2, or an equivalent amount of E2 conjugated to peroxidase, for different time intervals, and the intracellular cAMP levels were assessed. (Panels a 
and d) Cells were incubated at 4°C in defined medium (DM) either attached to a plate (open circles) or in suspension (closed circles). (Panels b and 
e) Attached cells were incubated at 37°C in DM medium (triangles) or DCSS medium (medium with 4 × dextran-coated charcoal-stripped serum; 
squares). (Panel c) Cells in suspension were stimulated with E2-peroxidase at 4°C. All experiments were repeated at least three times, and each time 
point was in triplicate. The data are presented as means ± standard error and the asterisks represent significant differences (P < 0.05) as compared 
with time 0.Available online http://breast-cancer-research.com/content/7/1/R101
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At 37°C, a low but significant degree of cAMP elevation
was achieved by 5 min in attached cells treated in DM (Fig.
2b, triangles); a greater cAMP response was achieved in
attached cells pre-incubated in DCSS (Fig. 2b, squares) as
compared with DM. All of the experiments conducted at
37°C were performed in the presence of 1 mmol/l IBMX, as
in most published protocols.
The impeded ligand E2-peroxidase also triggered produc-
tion of cAMP in suspended cells treated at 4°C in DM (Fig.
2c). The level of E2 presented by the conjugate in these
studies approximated the level applied as free steroid in the
experiments shown in the other panels. The resulting maxi-
mal level of accumulated cAMP was lower than that with
the equivalent amount of free ligand, but the time required
for peak accumulation was the same.
MCF-7 cell line depleted for membrane ER-α
When treated at 4°C in suspension, mERlow MCF-7 cells
exhibited only a small but significant rise in cAMP (Fig. 2d)
in response to E2. Hormone treatment caused a maximal
accumulation of cAMP at 6–15 min, but the decay in this
second messenger was very rapid. Insignificant changes
were observed at 37°C in attached cells, both in serum-
containing and in defined media (Fig. 2e). The statistical
comparison of cAMP accumulated in mERhigh versus mER-
low cells revealed that those differences were significant.
cAMP dynamics
Because our 4°C protocol without any added IBMX is rela-
tively unusual, we wondered about the causes of the cAMP
level dynamics. We next asked why accumulated cAMP did
not plateau at 37°C. That is, what are the circumstances of
cAMP decay in these cells, and does cAMP leave the cells
or is it metabolized? To approach these questions we
measured cAMP levels at 37°C after 1 pmol/l E2 stimula-
tion, in cells and in their extracellular medium in parallel. We
also measured the kinetics of IBMX protection of cAMP by
measuring the decrease in cAMP in the cytosolic fraction
prepared from cells that had been treated with forskolin.
The increase in cAMP in the medium did not match the
decrease in intracellular cAMP content of the cell; although
the intracellular cAMP of this population of cells decreased
by about 80 pmol (from 95 pmol down to 15 pmol), the
cAMP in the medium increased only by about 3 pmol (Fig.
3a). As expected, in the absence of IBMX the decrease in
cytosolic cAMP was rapid (3.8%/min), whereas in the pres-
ence of IBMX it decreased at a slower rate (1.2%/min).
Therefore, the addition of IBMX protected cAMP from the
action of some PDEs (Fig. 3b), but there was still a signifi-
cant fraction of cAMP that seemed refractory to this
protection.
ICI172,780 and 17α-estradiol effects on cAMP 
production
ICI172,780 was effective in preventing the 15 min maximal
cAMP accumulation (Fig. 4a). Simultaneous application of
ICI172,780 (1 µmol/l) and E2 (1 pmol/l) was as effective as
the 30 min pretreatment with ICI172,780. The usually inac-
tive E2 stereoisomer 17α-estradiol (10 nmol/l) was not
capable of triggering cAMP production in mERhigh MCF-7
Figure 3
Kinetics of cAMP decrease in MCF-7 cells enriched for membrane  estrogen receptor-α (mERhigh) cells Kinetics of cAMP decrease in MCF-7 cells enriched for membrane 
estrogen receptor-α (mERhigh) cells. (a) Cells were treated with 1 pmol/
l 17β-estradiol (E2) for different time intervals at 37°C in the presence 
of 1 mmol/l 3-isobutyl-1-methylxanthine (IBMX). The intracellular cAMP 
(circles) and that in the medium (squares) from the same cells were 
assessed. (b) cAMP was produced by directly stimulating adenylyl 
cyclase with 10 µmol/l forskolin for 15 min at 37°C. The decrease in 
cAMP in the cytosol was tested at 37°C in the absence (open circles) 
and presence of 1 mmol/l IBMX (closed circles). The entire regression 
lines were compared by evaluating the differences between the sums of 
squares of the residuals of individual lines with the sum of squares of 
the residuals of the combined line using an F-test. The data are pre-
sented as means ± standard error. The regression lines were signifi-
cantly different (P = 0.0001).Breast Cancer Research    Vol 7 No 1    Zivadinovic et al.
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cells (Fig. 4b). These studies are consistent with this effect
being mediated by known ER proteins.
E2-induced dose-responses of cAMP levels and cell 
number changes differ between MCF-7 cells enriched 
and depleted for membrane ER-α
In Fig. 2 we observed that the characteristics of hormonally
induced cAMP accumulation differed between mERhigh and
mERlow cells. Figure 5a shows that the E2 dose–response
curve for this response was biphasic in both cell types, but
the sensitivity and upper limit of the responses differed. The
mERhigh cells exhibited a higher maximal response level in
cAMP levels. In mERlow  cells the response peak was
achieved with a 50-fold lower E2 concentration; the higher
maximal stimulation of cAMP production in mERhigh cells
was achieved with 100 pmol/l E2. Therefore, it can be
assumed that a larger number of receptors had to be filled
to achieve this higher response level in cells that had a
larger receptor pool.
E2 also caused different dose effects on the proliferation of
mERhigh versus mERlow cells. Cells with low mER levels
responded to E2 with stimulated proliferation in the whole
range of tested concentrations (from 0.1 fmol/l up to 0.1
mmol/l; Fig. 5b, open circles). However, mERhigh  cells
showed a biphasic proliferation pattern, with growth stimu-
lation in the lowest range of concentrations of E2 (up to 1
pmol/l) and inhibited proliferation at higher E2 concentra-
tions (from 1 nmol/l up to 1 mmol/l; Fig. 5b, closed circles).
Therefore, the higher levels of cAMP production achieved
with mERhigh cells result in growth inhibition.
Because we had previously observed an effect of cell den-
sity on the level of mER expression and corresponding
functional consequences in pituitary tumor cells, we won-
dered whether cell density would affect functional
responses to E2  in this breast cancer model system.
Indeed, proliferation of mERhigh cells in the presence of 10
nmol/l E2 was influenced by cell density (Fig. 6). At a low
density (such as that used in the preceding experiments)
proliferation was inhibited, whereas at higher cell densities
this effect was reversed. When the cells were plated at the
highest density studied (6000/well), their growth was stim-
ulated at the same level as were the mERlow cells. In con-
trast, proliferation of mERlow  cells was stimulated
regardless of the cell plating density.
E2-induced increase in adenylyl cyclase activity 
correlates with decreased proliferation of MCF-7 cells 
enriched for membrane ER-α cells via a PKA-activated 
pathway
An activator of AC (forskolin), as well as the cell-permeable
cAMP analog 8-CPT cAMP, inhibited the growth of both
mERhigh and mERlow cells (Figs 7 and 8) when provided in
the same concentrations to both cell types. In mERhigh cells,
both the AC inhibitor SQ22,536 and the PKA inhibitor H-
89 abrogated E2-induced inhibition of cell proliferation
(Figs 7 and 8). Both inhibitors increased the stimulatory
effect of E2 on mERlow cell proliferation (Fig. 8). Therefore,
bypassing receptor-mediated signaling mechanisms and
controlling cAMP levels with other compounds (which
either provided or acted to generate cAMP) made both cell
types behave similarly with respect to changes in cell
number. Likewise, artificially decreasing cAMP levels or
their downstream effects (AC and PKA inhibitors) made
Figure 4
Effects of ICI172,780 and 17α-estradiol on cAMP production in MCF- 7 cells enriched for membrane estrogen receptor-α (mERhigh) cells Effects of ICI172,780 and 17α-estradiol on cAMP production in MCF-
7 cells enriched for membrane estrogen receptor-α (mERhigh) cells. (a) 
ICI172,780 inhibited 17β-estradiol (E2)-induced cAMP production. 
Both simultaneous application of 1 µmol/l ICI172,780 and 1 pmol/l E2 
(open circle) or 30 min pretreatment with ICI172,780 (open square) 
was tested. (b) 17α-Estradiol was applied at a 10 nmol/l concentration 
and the time dependent cAMP production was followed. Closed circles 
represent E2 induced cAMP production, redrawn for comparison from 
Fig. 2a.Available online http://breast-cancer-research.com/content/7/1/R101
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cells respond similarly with respect to growth, regardless of
their mER levels.
Discussion
Our studies provide evidence that membrane-associated
ERs participate in the estrogen-regulated control of MCF-7
breast cancer cell number by changing cAMP levels and
downstream cAMP-activated PKA. E2 differentially influ-
enced cell proliferation in mERhigh versus mERlow cells.
Measurements of and responses to cAMP manipulated via
different culture conditions, assay incubation conditions,
and specific response mimetics or inhibitors allowed us to
implicate pathways and signal levels in the mechanism of
control of cell number, and to suggest possible resolutions
between previously reported conflicting results about
cAMP and the control of breast cancer cell growth.
Breast cancer cell lines (especially MCF-7 cells) are heter-
ogeneous populations of cells; other investigators have
succeeded in separating them into different constituent
subpopulations [20,21]. We exploited this characteristic
and separated MCF-7 cells into populations enriched and
depleted for the membrane subform of ER-α by capturing
live cells that bound ER-α-specific antibody to their mem-
branes. These two cell subtypes express the same level of
Figure 5
17β-Estradiol (E2) dose-dependent cAMP responses and proliferation  in MCF-7 cells enriched for membrane estrogen receptor-α (mERhigh;  closed circles) versus MCF-7 cells depleted for membrane estrogen  receptor-α (mERlow; open circles) 17β-Estradiol (E2) dose-dependent cAMP responses and proliferation 
in MCF-7 cells enriched for membrane estrogen receptor-α (mERhigh; 
closed circles) versus MCF-7 cells depleted for membrane estrogen 
receptor-α (mERlow; open circles). (a) cAMP response; each experi-
ment was repeated three times with triplicate samples, and the data 
were approximated with a four-parameters Gaussian equation. The two 
sets of data were compared by evaluating the differences between the 
sums of squares of the residuals from each individual curve with the 
sum of squares of the residuals of the combined curve using the F-test. 
The curves were significantly different (P = 0.02). (b) E2 dose-depend-
ent proliferation curves vary with mER expression level. mERhigh cells 
(closed circles) exhibited a biphasic growth pattern, whereas mERlow 
cells (open circles) responded with a sigmoid growth pattern. The cells 
were treated on separate plates with different concentrations of E2 or 
ethanol vehicle (0.1%) for 5 days. The data are percentages of control, 
and expressed as mean values ± standard error from three separate 
experiments, each containing 40 replicates.
Figure 6
Effect of cell density on 17β-estradiol (E2)-induced proliferation Effect of cell density on 17β-estradiol (E2)-induced proliferation. Differ-
ent densities of MCF-7 cells enriched for membrane estrogen receptor-
α (mERhigh; shaded bars) and MCF-7 cells depleted for membrane 
estrogen receptor-α (mERlow; open bars) were treated for 5 days with 
10 nmol/l E2. The controls were treated on a separate plate with etha-
nol vehicle (0.1%). Values are expressed as percentage change from 
control. All experimental mean values (error bars are ± standard error) 
were significantly different (P < 0.002) from the control (first bar on the 
left).Breast Cancer Research    Vol 7 No 1    Zivadinovic et al.
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total (membrane plus nuclear) ER [22]. Thus, we have a
system in which the consequences of mER levels can be
assessed in the same cell line, without other transgenetic
manipulations. Because our mERhigh and mERlow cells were
not clonally derived (from a single cell), the differences
between these populations that we observed can not be
attributed to clonal variations.
Attempts to study E2-stimulated cAMP levels using the
conditions reported by others for MCF-7 cells [23-25]
resulted in variable and marginal responses in our hands.
We tested different incubation times from 10 min up to 3
hours at 37°C, and all were relatively ineffective, even in the
presence of a PDE inhibitor. When we decreased the incu-
bation temperature to 4°C, the amplitude of maximally
accumulated cAMP increased and the slope of its decline
decreased considerably. Although this temperature is not
physiologic, it is often applied for biochemical assessment
of biologic responses. This is done to avoid competition by
other biologic responses that could rapidly remove the mol-
ecule under study at the physiologic temperature.
We also tested a variety of other conditions, including
much shorter incubation times than 10 min and various
media, as well as comparing attached versus suspended
cell preparations. Both we and others [24] have found an
influence of charcoal-stripped serum in the medium on
cAMP production. However, whereas Fortunati and cow-
orkers [24] could not identify any cAMP production in
serum-free medium, we were able to detect a low but sig-
nificant E2-induced increase. It is possible that this discrep-
ancy could be due to different incubation times, as we
found a very rapid effect (3 min) but the other study tested
15 min as the earliest time point. In more recent analyses it
has become common to observe nongenomic responses
that are complete and return to baseline by 15 min [26-28].
In our cells 1 mmol/l IBMX was only partially effective, and
loss of cAMP was not the consequence of its transport out
of the cells. We can assume that some other PDEs that are
resistant to IBMX were present, unless our mERhigh cells
possess other cAMP effectors (receptors or binding pro-
teins) apart from PKA [29] that could capture cyclic nucle-
Figure 7
Signaling pathway inhibitors differentially affect cell proliferation Signaling pathway inhibitors differentially affect cell proliferation. 17β-
Estradiol (E2; 10 nmol/l) was introduced on day 0. Adenylyl cyclase 
stimulator (forskolin; 10 µmol/l) and cAMP analog (8-CPT cAMP; 250 
µmol/l) were replenished every second day. PKA inhibitor (H-89; 10 
µmol/l) and adenylyl cyclase inhibitor (SQ 22,536; 300 µmol/l) were 
applied at day 0 together with 10 nmol/l E2. Cells were fixed on days 1, 
3 and 5, and their number estimated by crystal violet (CV) assay. The 
data are averaged values ± standard error (error ranges were very small 
and are contained within the size of the symbol) of two separate experi-
ments, each containing 24 replicates. mERhigh, MCF-7 cells enriched 
for membrane estrogen receptor-α; mERlow, MCF-7 cells depleted for 
membrane estrogen receptor-α.
Figure 8
Proliferation of cells after 5 days of treatment with different compounds Proliferation of cells after 5 days of treatment with different compounds. 
The same incubation conditions apply as for Fig. 7. The asterisks indi-
cate significant differences (P < 0.002) from controls. Data are 
expresssed as means ± standard error. E2, 17β-estradiol; mERhigh, 
MCF-7 cells enriched for membrane estrogen receptor-α; mERlow, 
MCF-7 cells depleted for membrane estrogen receptor-α.Available online http://breast-cancer-research.com/content/7/1/R101
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otides and render them undetectable in our cytosol assay.
The possibility of multiple PDEs with their own individual
patterns of regulation provide significant alternative
opportunities for control of this important cell function, and
add another level of complexity to its analysis.
The impeded ligand that we used in these studies, E2-per-
oxidase, was also capable of triggering cAMP accumula-
tion. The attachment of E2 to a large molecule that cannot
easily enter cells has previously been used to demonstrate
action at the membrane [30-33]. Although this compound
stimulated lower but significant levels of cAMP accumula-
tion than did approximately equivalent levels of free steroid,
it is likely that steric considerations (such as only partial
contact of the large molecule with the cell surface; bound
protein obscuring adjacent receptors) may prevent ligand–
receptor contacts, or that some other aspect of the ligand–
receptor complex configuration is disrupted by ligand teth-
ering. Others have also reported that E2-peroxidase has
lower affinity for the receptor compared with free ligand
[34]. Although it has been reported that steroid can escape
conjugates and elicit a response, we removed free steroid
in our studies by incubating an aliquot with dextran-coated
charcoal under conditions that remove more than 99% of
free hormone [35] just prior to application of the impeded
ligand. The release of steroid from conjugates happens
over a much longer period of time than a rapid response
[36].
We have shown that E2 can play a dual role in breast can-
cer cells, both stimulating and inhibiting cell proliferation,
depending on its concentration, which is consistent with
the findings reported by Lippert and coworkers [37]. We
have also shown that the same E2 concentration (10 nmol/
l) could either prevent or enhance mERhigh MCF-7 cell
growth, depending on cell density. We previously showed
that increased cell density can dramatically decrease the
fraction of ER-α expressed in the cell membrane (see
accompanying reports [18] and [22]), and others have
observed similar effects on other membrane receptors
[18,38]. The estrogenic responses of mERlow cells were
not affected by cell density, and their mER levels were
already low. We therefore suggest that this type of control
can be attributed to effects on the level of mER and thus
the signaling cascades elicited by it.
It remains to be determined whether E2-induced apoptosis,
necrosis, or cell growth arrest could be part of the negative
growth effects caused by high E2 levels in mERhigh cells.
Others have shown that very low concentrations of E2 (as
low as 1 pmol/l) induce apoptosis in MCF-7 LTED cells
[39], selected by long-term growth in the absence of estro-
gens. The resulting increase in ER-α expression levels in
these cells caused hypersensitivity to E2 [40]. In addition,
cells in which ER-α has been over-expressed by stable
transfection also die in response to physiologic estrogen
concentrations [41]. However, measurements in both of
these studies failed to distinguish between nuclear and
membrane forms of ER-α. Because our mERhigh cells were
selected on the basis of their high mER expression levels
(see accompanying report [22]), we can assume that their
higher sensitivity to E2 is a consequence of their mER lev-
els. Our mERhigh  cells exhibited a biphasic pattern of
proliferation, with the maximal growth at approximately 10-
11 mol/l E2 and the decline in cell number beginning in
response to approximately 1 nmol/l E2. Maximal stimulation
of LTED cells was achieved at 10-14 mol/l, while stimulation
of wild-type MCF-7 cells was maximal at 10-10 mol/l E2.
Hence, our mERhigh  cells exhibit an intermediary
proliferation pattern between wild-type and MCF-7 LTED
cells with respect to the E2 dose–response curves reported
by Santen and coworkers [21].
Our mERlow  cells responded to E2  by dose-dependent
enhancement of their cell numbers. These cells have much
lower levels of mER but some is present, and they express
the intracellular ER at comparable levels to mERhigh cells
(see accompanying report [22]). MCF-7 breast cancer
cells have also been shown to respond to E2 as an apopto-
sis survival factor after taxol or ultraviolet exposure [42].
This protective effect was directly dependent on the con-
centration of E2, and the highest effect was achieved with
10 nmol/l E2. This inhibition of apoptosis was also achieved
with E2–bovine serum albumin, which indicated probable
mediation through a plasma membrane ER. However, these
studies did not directly assess the cellular level of mER (the
populations studied were probably mixed, comprising cells
with both high and low levels of mER). Therefore, it is hard
to correlate their heterogeneous cell population results with
our selected mERhigh or mERlow cells. Whether protection
from apoptosis plays any role in the survival of our mERlow
cells remains to be determined.
Our findings also demonstrated that cAMP-activated PKA
activity is associated with inhibition of cell proliferation. In
mERhigh cells H-89 blocked the decrease in cell number
caused by 10 nmol/l E2, and in mERlow cells it further
enhanced the already existing stimulation of proliferation. It
is still not clear how cAMP inhibits cell proliferation. Lowe
and coworkers [43] suggested that the inhibitory effect of
cAMP (and forskolin, which induced it) occurs distal to
extracellular signal-regulated kinase (ERK) activation, pos-
sibly by the inhibition of an ERK-independent pathway.
However, other groups have reported that the cAMP/PKA
pathway and mitogen-activated protein kinase (MAPK)
pathway are connected in fibroblasts [43,44] and in MCF-
7 cells [45,46]. Activated PKA phosphorylates Raf and
inhibits phosphorylation of downstream MEK1/2 and Erk1/
2, thus preventing proliferation, a counterbalance to E2-
stimulated pathways that stimulate proliferation (Fig. 9).Breast Cancer Research    Vol 7 No 1    Zivadinovic et al.
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Our findings are consistent with the participation of PKA in
inhibition of cell proliferation.
In mERlow cells, at both low (1 pmol/l) and high (10 nmol/l)
E2 concentrations, a very low amount of cAMP accumu-
lated. Therefore, in these cells cAMP's inhibitory
concentration is never achieved, although further inhibition
of cAMP and its downstream effects (via inhibitors) could
still enhance proliferation. In mERhigh cells, however, both
low and high E2 concentrations caused about the same
amount of cAMP accumulation, but only at 10 nmol/l E2 did
the inhibitory pathway prevail. This finding suggests that
the model depicted in Fig. 9 is simplified, and that other
pathways participate and integrate at other levels, resulting
in modulation of the cell's decision to proliferate, arrest, or
die. It was recently shown that E2 simultaneously activates
the proliferative MAPK-Erk (via Src-Shc-Ras-Raf-MEK-Erk)
and phosphatidylinositol-3 kinase pathways in MCF-7 cells,
and that both pathways are required to trigger S-phase
entry of cells. In addition, the temporal pattern of their acti-
vation is extremely important; a necessary immediate and
transient consequence of hormone treatment is MAPK acti-
vation, whereas phosphatidylinositol-3 kinase activation
must be sustained for at least 3 hours [47]. Our results rep-
resent a unique example of the extremely complex effects
of steroid on target tissues, and emphasize the importance
of a global approach when studying the proliferative effects
of estrogens.
Reports from other groups have indicated that there may
be other membrane estrogen receptor types, such as
GPR30 [48] and SHBG-R [24,49], which participate in E2
signaling from the membrane. Clearly, a detailed analysis of
different mER levels on the same cell backgrounds from a
variety of responsive tissue types would be a valuable addi-
tion to these investigations. Finally, estrogen-dependent
breast cancer cells synthesize and secrete growth factors
in response to E2 which can stimulate the epidermal growth
factor receptor signaling pathway to induce proliferation
[50]. Therefore, comparative studies of the contributions of
each of these possible players are needed if we are to gain
a complete understanding of E2-induced proliferation of
breast cancer cells.
Conclusion
Our results indicate that a membrane-associated ER-α is
responsible for rapid E2-induced cAMP accumulation and
subsequent activation of the downstream PKA pathway. A
high level of stimulation through the mER-α results in an
interruption to breast cancer cell proliferation. Thus, knowl-
edge of tumor mER-α levels and manipulation of estrogenic
compound doses and resulting signaling mechanisms may
offer an opportunity to refine treatment strategies for some
patients with tumors that have these characteristics.
Competing interests
The author(s) declare that they have no competing
interests.
Acknowledgements
We thank Dr David Konkel for critical review of our paper. This work was 
supported by the grant from Department of Defense Breast Cancer 
Research Program, DAMD17-01-1-0418.
References
1. Leung PCK, Steele GL: Intracellular signaling in the gonads.
Endocrine Reviews 1992, 13:476-498.
2. Stumpel F, Scholtka B, Jungermann K: Stimulation by portal
insulin of intestinal glucose absorption via hepatoenteral
nerves and prostaglandin E2 in the isolated, jointly perfused
small intestine and liver of the rat. Ann N Y Acad Sci 2000,
915:111-116.
3. Lohmann SM, Fischmeister R, Walter U: Signal transduction by
cGMP in heart. Basic Res Cardiol 1991, 86:503-514.
4. Albrecht ED, Pepe GJ: Placental steroid hormone biosynthesis
in primate pregnancy. Endocr Rev 1990, 11:124-150.
5. Wood JR, Strauss JF III: Multiple signal transduction pathways
regulate ovarian steroidogenesis.  Rev Endocr Metab Disord
2002, 3:33-46.
6. Dremier S, Coulonval K, Perpete S, Vandeput F, Fortemaison N,
Van Keymeulen A, Deleu S, Ledent C, Clement S, Schurmans S,
et al.: The role of cyclic AMP and its effect on protein kinase A
in the mitogenic action of thyrotropin on the thyroid cell. Ann
N Y Acad Sci 2002, 968:106-121.
Figure 9
Possible negative feedback effects of estrogen-activated cAMP-PKA  (protein kinase A) pathway on the estrogen-activated Ras-Raf-MAPK  (mitogen-activated protein kinase) pathway of cell proliferation Possible negative feedback effects of estrogen-activated cAMP-PKA 
(protein kinase A) pathway on the estrogen-activated Ras-Raf-MAPK 
(mitogen-activated protein kinase) pathway of cell proliferation. The up 
arrow indicates a cAMP increase. AC, adenylyl cyclase; E2, 17β-estra-
diol; ERK, extracellular signal-regulated kinase; MEK, MAPK kinase.Available online http://breast-cancer-research.com/content/7/1/R101
R111
7. Tierney T, Robinson ICAF: Increased lactotrophs despite
decreased somatotrophs in the dwarf (dw/dw) rat: a defect in
the regulation of lactotroph/somatotroph cell fate?  J
Endocrinol 2002, 175:435-446.
8. Starzec AB, Spanakis E, Nehme A, Salle V, Veber N, Mainguene
C, Planchon P, Valette A, Prevost G, Israel L: Proliferative
responses of epithelial-cells to 8-bromo-cyclic AMP and to a
phorbol ester change during breast pathogenesis.  J Cell
Physiol 1994, 161:31-38.
9. Cho-Chung YS: Suppression of malignancy targeting cyclic
AMP signal transducing proteins. Biochem Soc Trans 1992,
20:425-430.
10. Kim SN, Ahn YH, Kim SG, Park SD, Yoon SCC, Hong SH: 8-Cl-
cAMP induces cell cycle-specific apoptosis ln human cancer
cells. Int J Cancer 2001, 93:33-41.
11. Tang WJ, Yan S, Drum CL: Class III adenylyl cyclases: regula-
tion and underlying mechanisms.  Adv Second Messenger
Phosphoprotein Res 1998, 32:137-151.
12. Soderling SH, Beavo JA: Regulation of cAMP and cGMP signal-
ing: new phosphodiesterases and new functions. Curr Opin
Cell Biol 2000, 12:174-179.
13. Sutter-Dub MT: Rapid non-genomic and genomic responses to
progestogens, estrogens, and glucocorticoids in the endo-
crine pancreatic B cell, the adipocyte and other cell types. Ster-
oids 2002, 67:77-93.
14. Gametchu B: Glucocorticoid receptor-like antigen in lym-
phoma cell membranes: correlation to cell lysis. Science 1987,
236:456-461.
15. Pappas TC, Gametchu B, Watson CS: Membrane estrogen
receptor-enriched GH3/B6 cells have an enhanced non-
genomic response to estrogen. Endocrine 1995, 3:743-749.
1 6. G am et c hu  B,  W at s on  C ,  S hi h C , D as h ew  B :  Studies on the
arrangement of glucocorticoid receptors in the plasma mem-
brane of S-49 lymphoma cells. Steroids 1991, 56:411-419.
17. Campbell CH, Watson CS: A comparison of membrane vs.
intracellular estrogen receptor-alpha in GH3/B6 pituitary
tumor cells using a quantitative plate immunoassay. Steroids
2001, 66:727-736.
18. Campbell CH, Bulayeva N, Brown DB, Gametchu B, Watson CS:
Regulation of the membrane estrogen receptor-a: role of cell
density, serum, cell passage number, and estradiol. FASEB J
2002, 16:1917-1927.
19. Lottering M-L, Haag M, Seegers JC: Effects of 17β-estradiol
metabolites on cell cycle events in MCF-7 cells. Cancer Res
1992, 52:5926-5932.
20. Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE: Effect of
antiestrogens and aromatase inhibitor on basal growth of the
human breast cancer cell line MCF-7 in serum-free medium. J
Steroid Biochem Mol Biol 2003, 84:469-478.
21. Santen R, Jeng MH, Wang JP, Song R, Masamura S, McPherson
R, Santner S, Yue W, Shim WS: Adaptive hypersensitivity to
estradiol: potential mechanism for secondary hormonal
responses in breast cancer patients. J Steroid Biochem Mol
Biol 2001, 79:115-125.
22. Zivadinovic D, Watson CS: Membrane estrogen receptor-a lev-
els predict estrogen-induced ERK1/2 activation in MCF-7
cells. Breast Cancer Res 2004, 7:R130-R144.
23. Aronica SM, Kraus WL, Katzenellenbogen BS: Estrogen action
via the cAMP signaling pathway: stimulation of adenylate
cyclase and cAMP-regulated gene transcription.  Proc Natl
Acad Sci USA 1994, 91:8517-8521.
24. Fortunati N, Fissore F, Fazzari A, Piovano F, Catalano MG, Becchis
M, Berta L, Frairia R: Estradiol induction of cAMP in breast can-
cer cells is mediated by foetal calf serum (FCS) and sex hor-
mone-binding globulin (SHBG).  J Steroid Biochem Mol Biol
1999, 70:73-80.
25. Kiefer T, Ram PT, Yuan L, Hill SM: Melatonin inhibits estrogen
receptor transactivation and cAMP levels in breast cancer
cells. Breast Cancer Res Treat 2002, 71:37-45.
26. Boldyreff B, Wehling M: Rapid aldosterone actions: from the
membrane to signaling cascades to gene transcription and
physiological effects.  J Steroid Biochem Mol Biol 2003,
85:375-381.
27. Watson CS, Gametchu B: Membrane-initiated steroid actions
and the proteins which mediate them [review]. Proc Soc Exp
Biol Med 1999, 220:9-19.
28. Cato AC, Nestl A, Mink S: Rapid actions of steroid receptors in
cellular signaling pathways. Sci STKE 2002, 2002:RE9.
29. Chin KV, Yang WL, Ravatn R, Kita T, Reitman E, Vettori D, Cvijic
ME, Shin M, Iacono L: Reinventing the wheel of cyclic AMP:
novel mechanisms of cAMP signaling. Ann N Y Acad Sci 2002,
968:49-64.
30. Ropero AB, Soria B, Nadal A: A nonclassical estrogen mem-
brane receptor triggers rapid differential actions in the endo-
crine pancreas. Mol Endocrinol 2002, 16:497-505.
31. Pappas TC, Gametchu B, Watson CS: Membrane estrogen
receptors identified by multiple antibody and impeded ligand
labeling. FASEB J 1995, 9:404-410.
32. Norfleet AM, Clarke C, Gametchu B, Watson CS: Antibodies to
the estrogen receptor-a modulate prolactin release from rat
pituitary tumor cells through plasma membrane estrogen
receptors. FASEB J 2000, 14:157-165.
33. Watson CS, Norfleet AM, Pappas TC, Gametchu B: Rapid
actions of estrogens in GH3/B6 pituitiary tumor cells via a
plasma membrane version of estrogen receptor-alpha. Ster-
oids 1999, 64:5-13.
34. Jansson SE, Gripenberg J, Karonen SL, Wasenius VM, Pantzar P,
Kontula K, Karkkainen J, Adlercreutz H: Cytochemical demon-
stration of estrogen binding-sites in breast-cancer by estradiol
covalently linked to horseradish-peroxidase. Eur J Cancer Clin
Oncol 1985, 21:625-630.
35. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR: Human
vascular endothelial cells contain membrane binding sites for
estradiol, which mediate rapid intracellular signaling. Proc Natl
Acad Sci USA 2000, 97:5930-5935.
36. Binder M: Oestradiol-BSA conjugates for receptor histochem-
istry: problems of stability and interactions with cytosol. Histo-
chem J 1984, 16:1003-1023.
37. Lippert C, Seeger H, Mueck AO: The effect of endogenous
estradiol metabolites on the proliferation of human breast
cancer cells. Life Sci 2003, 72:877-883.
38. Scott CD, Baxter RC: Insulin-like growth factor-II receptors in
cultured rat hepatocytes: regulation by cell density.  J Cell
Physiol 1987, 133:532-538.
39. Song RX, Mor G, Naftolin F, McPherson RA, Song J, Zhang Z, Yue
W, Wang J, Santen RJ: Effect of long-term estrogen deprivation
on apoptotic responses of breast cancer cells to 17 beta-
estradiol. J Natl Cancer Inst 2001, 93:1714-1723.
40. Jeng MH, Shupnik MA, Bender TP, Westin EH, Bandyopadhyay D,
Kumar R, Masamura S, Santen RJ: Estrogen receptor expression
and function in long-term estrogen-deprived human breast
cancer cells. Endocrinology 1998, 139:4164-4174.
41. Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL: Construction
of cell lines that express high levels of the human estrogen
receptor and are killed by estrogens. Mol Endocrinol 1990,
4:1465-1473.
42. Razandi M, Pedram A, Levin ER: Plasma membrane estrogen
receptors signal to antiapoptosis in breast cancer.  Mol
Endocrinol 2000, 14:1434-1447.
43. Lowe WL Jr, Fu R, Banko M: Growth factor-induced transcrip-
tion via the serum response element is inhibited by cyclic ade-
nosine 3',5'-monophosphate in MCF-7 breast cancer cells.
Endocrinology 1997, 138:2219-2226.
44. Houslay MD, Kolch W: Cell-type specific integration of cross-
talk between extracellular signal-regulated kinase and cAMP
signaling. Mol Pharmacol 2000, 58:659-668.
45. Chen J, Bander JA, Santore TA, Chen Y, Ram PT, Smit MJ, Iyengar
R: Expression of Q227L-galphas in MCF-7 human breast can-
cer cells inhibits tumorigenesis. Proc Natl Acad Sci USA 1998,
95:2648-2652.
46. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M,
Di Marzo V: Involvement of the cAMP/protein kinase A pathway
and of mitogen-activated protein kinase in the anti-prolifera-
tive effects of anandamide in human breast cancer cells. FEBS
Lett 1999, 463:235-240.
47. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A,
Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A, et
al.: Sex steroid hormones act as growth factors. J Steroid Bio-
chem Mol Biol 2002, 83:31-35.
48. Filardo EJ, Quinn JA, Frackelton AR, Bland KI: Estrogen action via
the G protein-coupled receptor, GPR30: Stimulation of adeny-
lyl cyclase and cAMP-mediated attenuation of the epidermalBreast Cancer Research    Vol 7 No 1    Zivadinovic et al.
R112
growth factor receptor-to-MAPK signaling axis. Mol Endocrinol
2002, 16:70-84.
49. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA: Androgen
and estrogen signaling at the cell membrane via G-proteins
and cyclic adenosine monophosphate.  Steroids 1999,
64:100-106.
50. Keshamouni VG, Mattingly RR, Reddy KB: Mechanism of 17-
beta-estradiol-induced Erk1/2 activation in breast cancer
cells. A role for HER2 AND PKC-delta.  J Biol Chem 2002,
277:22558-22565.